EdiGene
13 known investors
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform. It focuses on treatments for genetic diseases and cancer.
Investors · 13
LAVHong Kong · $5M – $15M
Lilly Asia VenturesHong Kongvia Hongbo Lu · inferred
WI Harper GroupSan Francisco · $5M – $15M
3H Health InvestmentreportedShanghai
Alwin CapitalreportedGrand Cayman
BioTrack CapitalreportedGrand Cayman
IDG CapitalreportedHong Kong · $3M – $200M
Kunlun Capitalreported
Sherpa Healthcare PartnersreportedGrand Cayman
Also in the syndicate · 4
Huagai CapitalLilly Asia VentureLoyal Valley CapitalleadSequoia Capital China
Funding
SEC filings, press & company announcements$62M disclosed across 1 round · 2021
- $62Mseries B-plus financing roundApr 2021 · 4 sources
Loyal Valley Capital (lead), 3H Health Investment, Alwin Capital, BioTrack Capital, Huagai Capital, IDG Capital, Kunlun Capital, Lilly Asia Venture, Sequoia Capital China, Sherpa Healthcare Partners
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does EdiGene do?
- EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform. It focuses on treatments for genetic diseases and cancer.
- Who are EdiGene's investors?
- EdiGene's investors include LAV, Lilly Asia Ventures, WI Harper Group, 3H Health Investment, Alwin Capital, BioTrack Capital, IDG Capital, Kunlun Capital and 1 more.
- How much funding has EdiGene raised?
- EdiGene has disclosed $62M raised across 1 round.